SCHEMBL29806156

SCHEMBL29806156

COc1cnc(N(C(=O)OC(C)(C)C)c2ccc(C(F)(F)F)cc2)c(C#N)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 5/20 0.37
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ MT-CO2 P00403 1/20 0.33
▸ DYRK3 O43781 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ DYRK2 Q92630 1/20 0.33
▸ DYRK1B Q9Y463 1/20 0.33
▸ POLQ O75417 2/20 0.33
▸ CPB2 Q96IY4 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ RXRA P19793 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ NR1H3 Q13133 1/20 0.32
▸ SCN9A Q15858 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22931772 1.00 LIPE (0.37) LIPEABCG2MT-CO2DYRK3CCNA2
SCHEMBL29420832 0.90 RXRA (0.32) LIPEMT-CO2RXRANR1H2NR1H3
SCHEMBL22931775 0.90 RXRA (0.32) LIPEMT-CO2RXRANR1H2NR1H3
SCHEMBL22932341 0.80 XDH (0.33) LIPEMT-CO2MEN1KMT2ARXRA
SCHEMBL22932332 0.80 BCHE (0.34) MAPTLMNACACNA1BCACNA1C
SCHEMBL24755009 0.80 LIPE (0.35) LIPEABCG2MT-CO2DYRK3CCNA2
SCHEMBL29806705 0.80 LIPE (0.35) LIPEABCG2MT-CO2DYRK3CCNA2
SCHEMBL22931809 0.78 KDM4E (0.40) LIPEMT-CO2MEN1KMT2ARXRA
SCHEMBL22931787 0.78 MT-CO2 (0.37) LIPEMT-CO2RXRANR1H2NR1H3
SCHEMBL22931784 0.77 TRPM8 (0.33) RXRANR1H2NR1H3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003983-A1 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER Basilea Pharmaceutica International AG (CH) 2022-06-01 — — EP disclosed
Send feedback